



SoonerCare Fax Blast

January 13, 2010

SUBJECT: Statin Step Therapy

The step therapy requirements listed below will take effect January 25, 2010.

Tier 2 Approval Criteria:

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 1 medication that did not yield adequate LDL reduction.
2. Documented adverse effect or contraindication to all available lower tiered products.
3. Clinical exception for atorvastatin 80mg: members hospitalized for recent acute myocardial infarction or acute coronary syndrome.

Tier 3 Approval Criteria:

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 2 medication that did not yield adequate LDL reduction.
2. Documented adverse effect or contraindication to all available lower tiered products.
3. Clinical exceptions for Ezetimibe:
 - a. Documented active liver disease.
 - b. Documented unexplained, persistent elevations of serum transaminases.
 - c. Documented statin related myopathy.

HMG-CoA Reductase Inhibitors (Statins)		
Tier 1	Tier 2	Tier 3
fluvastatin (Lescol [®] & Lescol [®] XL)	Atorvastatin (Lipitor [®])	Lovastatin (brand Altoprev [®])
Lovastatin (Mevacor [®])	Rosuvastatin (Crestor [®])	Pravastatin/Aspirin (Pravaguard [®])
Pravastatin (Pravachol [®])		Simvastatin/Ezetimibe (Vytorin [®])
Simvastatin (Zocor [®])		Ezetimibe (Zetia [®])
Statin/Niaspan[®] Combination Products		
Tier 1 Statins and/or Niaspan [®]	Lovastatin/Niacin CR (Advicor [®])	
	Simvastatin/Niacin CR (Simcor [®])	